SOPHIA ANTIPOLIS, France – September 28, 2023 │Since the FDA approval of two CAR-T cell therapies in 2017, CAR therapy has gained a big interest. Indeed, KYMRIAH™ (tisagenlecleucel) from Novartis and YESCARTA™ (Axicabtagene Ciloleucel) from Kite Pharma, a Gilead company, received the first FDA approval for chimeric antigen receptor (CAR) therapy in 2017. These two[…]
SOPHIA ANTIPOLIS, France – August 31, 2023 │The quarterly report for the Q2 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on current dynamics in mRNA design. Exploring the dynamic activity of therapeutic mRNA innovations Therapeutic mRNA,[…]
SOPHIA ANTIPOLIS, France – August 10, 2023 │ The latest quarterly report of the RF Front-End Module & Components Patent Monitor is out! This is a good time to review what happened these last few years from a patent point of view, especially on LBAW filters (laterally excited or laterally coupled bulk acoustic wave filters).[…]
Monitoring litigations in the therapeutic mRNA field SOPHIA ANTIPOLIS, France – June 06, 2023 │ With the COVID-19 crisis, mRNA technologies have become key for numerous players. After the success of mRNA vaccine and the related hype, players are looking to settle their activity and strengthen their position. With this new phase comes litigations. Moderna[…]